Get the Stockscreener App
70.61
0.44%
-0.31
After Hours:
70.47
-0.14
-0.20%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $70.61, with a volume of 5.48M.
It is down -0.44% in the last 24 hours and up +35.81% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$70.92
Open:
$70.92
24h Volume:
5.48M
Relative Volume:
1.26
Market Cap:
$11.00B
Revenue:
$1.21B
Net Income/Loss:
$109.52M
P/E Ratio:
101.42
EPS:
0.6962
Net Cash Flow:
$269.60M
1W Performance:
-0.06%
1M Performance:
+35.81%
6M Performance:
+8.55%
1Y Performance:
+37.01%
1-Day Range:
$70.54
$70.98
1-Week Range:
$70.54
$71.00
52-Week Range:
$43.20
$72.16
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
70.61 | 11.05B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Activist investor Ananym urges Bio-Techne to consider selling - MSN
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com
List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn
Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com
TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus
TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus
$64.99 support anchors Bio-Techne stock near current levels - Traders Union
Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com
TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus
German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian
Is Bio-Techne stock underperforming the S&P 500? - MSN
Germany's Merck to buy Bio-Techne for $73 per share - MSN
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN
Germany's Merck to buy Bio-Techne for $11.3 billion - MSN
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN
Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
TECH Maintained by Baird -- Price Target Raised to $73.00 - GuruFocus
TECH Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion - MSN
Enterprise value to revenue forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Bio-Techne Corporation Actuals & Estimates (NASDAQ:TECH) - TradingView
Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools - Oncodaily
Taxation With Representation: Sidley, Paul Weiss, Kirkland - Law360
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH) - PR Newswire
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership - leadersleague.com
TECH Downgraded by Stephens & Co. -- Price Target Raised to $73. - GuruFocus
Merck KGaA Acquires Bio-Techne Corporation for 11.3 Billion Dollars - HarianBasis.co
Deutsche Bank cuts Bio-Techne stock rating on Merck acquisition By Investing.com - Investing.com Nigeria
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout - Citeline News & Insights
Bio-Techne Corporation (TECH) Merck KGaAM&A CallSlideshow (NASDAQ:TECH) 2026-06-26 - Seeking Alpha
Stephens Downgrades Bio-Techne to Equal Weight From Overweight, Adjusts Price Target to $73 From $68 - marketscreener.com
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout - Yahoo Finance
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets - marketscreener.com
Merck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocks - MSN
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Raises Price Target to $73 From $66 - marketscreener.com
Merck KGaA's Bio-Techne Deal Seems a Strong Fit -- Market Talk - Moomoo
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $66 - marketscreener.com
Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain CircumstancesSEC Filing - TradingView
Bio-Techne (TECH) Sees Significant Price Surge - GuruFocus
Merck KGaA (MKGAF) Acquires Bio-Techne (TECH) for $73 per Share - GuruFocus
Merck to buy Bio-Techne (NASDAQ: TECH) in $73 per share all-cash deal - Stock Titan
Bio-Techne retention bonuses approved for Kim Kelderman, Jim Hippel - TradingView
Merck Pulls Off Biggest Deal in a Decade With $11.3 Billion Bio-Techne Acquisition - finance.biggo.com
5 Stocks Winning by Double Digits - Insider Monkey
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
May 08 '26 |
Sale |
48.28 |
6,636 |
320,386 |
200 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):